Abemaciclib shows benefit in dedifferentiated liposarcoma
Published on 31 May 2026
Dr Mark Dickson talks to ecancer at ASCO 2026 about findings from a phase III trial evaluating abemaciclib in patients with recurrent dedifferentiated liposarcoma.
Reviewing the study design, efficacy outcomes including progression-free survival, and the safety profile observed in the trial, he notes the potential clinical implications for management of this rare soft tissue sarcoma.
This information is intended for health care professionals only. The information is not intended for US health care professionals.